Abstract:What is known and ObjectiveAlthough ticagrelor has been well‐known to improve clinical outcomes in patients undergoing percutaneous coronary intervention (PCI), and its effectiveness and safety have not been well evaluated in Chinese patients. This study aimed to evaluate the effectiveness and safety of ticagrelor in Chinese patients. In order to find potential effect modifiers on the drug effects, a decision tree method was performed to detect interactions between treatment and patient characteristics in an automatic and systematic manner. MethodsThis retrospective study included acute coronary syndrome (ACS) patients who underwent PCI and received either ticagrelor (N = 250) or clopidogrel (N = 291) while hospitalized between August 2014 and August 2015. After propensity score matching, Kaplan‐Meier analysis was used to study the event‐free survival against major adverse cardiovascular events (MACE, primary efficacy outcome, defined as the composite of cardiac death, non‐fatal myocardial infarction [MI], stroke, restenosis and target vessel revascularization [TVR]), re‐hospitalization, the need for urgent re‐PCI (secondary efficacy outcome) and bleeding events (safety outcome) within 12 months of the PCI date. To search for effect modifiers of the two antiplatelet therapies, a machine‐learning decision tree algorithm was conducted to predict re‐hospitalization status. ResultsAfter propensity score matching (N = 442), ticagrelor and clopidogrel had no significant difference in MACE, re‐hospitalization and bleeding. The decision tree analysis showed that the number of diseased vessels modulated the effect of ticagrelor and clopidogrel on re‐hospitalization rates. In single‐vessel disease (SVD) patients, ticagrelor was associated with lower hazards than clopidogrel for all efficacy outcomes: MACE (HR = 0.190, 95% CI: 0.042–0.866), re‐hospitalization (HR = 0.296, 95% CI: 0.108–0.808), urgent re‐PCI (HR = 0.249, 95% CI: 0.069–0.895), bleeding (HR = 1.006, 95% CI: 0.063–16.129). However, in multi‐vessel disease (MVD) patients, the two treatments did not show significant difference. What is New and ConclusionIn the general patient population, there was no significant difference between ticagrelor and clopidogrel on the hazard of MACE. However, ticagrelor achieved a better effectiveness than clopidogrel in patients with SVD. This pilot study provides scientific basis to call for a large‐scale prospective study in this population.

Analysis of clinical application of ticagrelor, a new oral antiplatelet drug

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.

Ticagrelor in the Treatment of Acute Coronary Syndrome: Health Technology Assessment

Ticagrelor Versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome: A Pharmacodynamic Analysis.

Progress in the clinical effects and adverse reactions of ticagrelor

Ticagrelor: Positive, Negative and Misunderstood Properties As a New Antiplatelet Agent

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update

Pharmacodynamics, Pharmacokinetics, and Safety of Ticagrelor in Chinese Patients with Stable Coronary Artery Disease.

Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese Subjects

Research on different ticagrelor dosage in elderly patients undergoing percutaneous coronary intervention

Use of Ticagrelor As Antiplatelet Therapy in Patients with Unstable Angina Pectoris after Undergoing Percutaneous Coronary Interventions:A Clinical Observation

Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A GRACE Risk Score Stratification-Based Analysis in a Large-Scale, Real-World Study From China

Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine‐learning decision tree approaches

Efficacy of ticagrelor and clopidogrel in patients with acute coronary syndrome after elective percutaneous coronary intervention

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS

Association of ticagrelor vs clopidogrel with net adverse clinical events in NSTEMI patients with mild thrombocytopenia

Effect and Safety of Ticagrelor on Patients with Acute Coronary Syndrome

Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review

Novel antiplatelet agent ticagrelor

Association of ticagrelor vs clopidogrel with net adverse clinical events in STEMI patients with mild thrombocytopenia